We discuss management of eyes with both geographic atrophy and neovascular AMD with Dr. Ted Leng of the Byers Eye Institute, Stanford University School of Medicine
We review the 6 month results of the Davio 2 trial of the Durayvu TKI delivery system for maintenance therapy of neovascular AMD with Dr. Carl Regillo of Wills Eye Hospital.
We discuss the latest promising results from the GALE extension study of pegcetacoplan with Dr. Ashkan Abbey of Texas Retina Associates
We discuss the promising phase I results of the Helios trial studying AXPAXLI TKI inhibitor implant for diabetic retinopathy with Dr. Dilsher Dhoot of California Retina Consultants.
We discuss the use of non steroidal inflammatory agents in the management of central serous chorioretinopathy with Dr. Michael Singer of San Antonio, Texas
We discuss remarkable preliminary results from the the use of intravitreal EYE-103, a novel Wnt pathway agonist in the treatment of DME and neovascular AMD with Dr. Charles Wykoff of Houston Texas.
We discuss the first interim results of a novel intravitreal gene therapy agent, 4D-150, with Dr. Arshad Khanani of Sierra Eye Associates and the University of Nevada Reno School of Medicine.
We discuss the use of a novel bispecific anti-VEGF Anti IL-6 Antibody Biopolymar Conjugate for the treatment of DME with Dr. Mark R. Barakat of Phoenix, AZ.
We discuss the occurrence of retinal vasculitis following pegcetcoplan therapy of geographic atrophy with Dr. Andrew Witkin of the New England Eye Center, Tufts University School of Medicine
We discuss the treatment results of high dose aflibercept in the eyes in the most severe quartile of diabetic macular edema with Dr. Roger Goldberg of Walnut Creek, California.
We discuss the use of an IL-6 inhibitor in the treatment of uveitis macular edema with Dr. Sumit Sharma of the Cole Eye Institute, Cleveland Clinic.
We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.
We discuss the unique results of the Annexon geographic atrophy Phase I clinical trial with Dr. Roger Goldberg of Bay Area Retina Associates, Walnut Creek, California
We review the latest diagnostic and therapeutic approaches for retinoblastoma with Dr. Jesse Berry, Associate Professor of Ophthalmology, Children's Hospital Los Angeles.
We discuss the feasibility of using home OCT vs. a treat and extend approach in a clinical trial of faricimab in neovascular AMD with Dr. Kevin Blinder of the Retina Institute in Saint Louis, Mo and Profesor of Ophthalmology at Washington University School of Medicine.
We discuss the characteristics of eyes with the best visual outcomes in the Davio trial of TKI EY-1901 with Dr. Philip Storey of the Austin Retina Associates, Austin, Texas.
We discuss a post-hoc study comparing the efficacy of Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) with Paul Hahn, MD, PhD, of NJ Retina.
We discuss a comparative trial of preventive therapy for non-proliferative retinopathy vs. ad hoc treatment of disease complications with Dr. Hani Salehi-Had of Retina Associates of Southern California, Huntington Beach, California.
We discuss the latest information on phase 2 trials of gene therapy for x-linked retinitis pigmentosa with Dr. Nadia Waheed, Chief Medical Officer of Beacon Therapeutics and Associate Professor of Ophthalmology at the New England Eye Center, Tufts University School of Medicine.
We discuss the use of optogenetics for the treatment of inherited retinal degenerations with Dr. Jose Sahel, Chairman and Distinguished Professor of Ophthalmology at the University of Pittsburgh School of Medicine.
We discuss the importance of intensive therapy of DME, when using aflibercept for DME, as suggested by a review of real world cases from the Vestrum data base, with Dr. Ferhina Ali, Assistant Professor of Ophthalmology, New York Medical College
We discuss the use of a topical agent for the treatment of diabetic macular edema with Dr. Arshad Khanani, Director of Research, Sierra Eye Associates, Associate Clinical Professor of Ophthalmology, University Nevada School of Medicine, Reno.
We review novel approaches for the treatment of intermediate AMD, with Dr. Barry Kuppermann, Director Gavin Herbert Eye Institute, Chairman Department of Ophthalmology, University of California Irvine, Steinert Endowed Chair.
In our latest update, we discuss safety issues associated with retinal gene therapy with Professor Glenn Yiu of the University of California School of Medicine.
We discuss the use of a novel oral agent for the treatment of diabetic retinopathy with David R. Lally, MD, Director of Research, New England Retina Consultants, Springfield, MA
We discuss intravitreal gene therapy with a new agent, 4D-150 with Veeral Sheth, MD, MBA Assistant Clinical Professor of Ophthalmology University of Illinois at Chicago.
We discuss the use of optogenetics in the treatment of retinal degenerations with Dr. Michael Singer, Adjunct Professor of Ophthalmology, University of Texas Health Science Center, San Antonio.
We discuss retinal drying in diabetic macular edema using the Iluvien implant with Dr. Michael Singer, Adjunct Professor, University of Texas Health Science Center, San Antonio.
We discuss the use of blockade of VEGF C and D in the treatment of neovascular AMD with Dr. Dante Pieramici, California Retina Research Foundation, California Retina Consultants.
We discuss the use of a novel treatment approach, senolytic therapy, for the treatment of diabetic macular edema with Dr. David Boyer, Adjunct Professor, USC Roski Eye Institute.
